Translational Development Acquisition Corp. (TDAC) has amended its previously announced agreement to merge with ProLogium Holding Inc. The amendment, entered into on November 16, 2026, modifies the Business Combination Agreement signed on May 27, 2026. The transaction remains pending, with the amendment adjusting specific mechanics regarding the capital structure of ProLogium and the post-merger governance of the combined entity.

The amendment defines the Equity Value of the transaction at $3.9 billion, comprising an enterprise value of $3.8 billion plus agreed net cash of $100 million. To determine the per-share equity value, the filing establishes a fixed "Aggregate Company Shares" total of 93,682,924. This figure includes 89,441,230 issued and outstanding shares, 2,581,694 shares underlying outstanding warrants, and 1,660,000 shares reserved for equity incentive plans. Based on this calculation, the Consolidation Factor is set at 4.16.

Under the revised terms, the share consolidation mechanism is replaced with a share exchange. On the closing date, ProLogium will issue new Class A, Class B, or Class C ordinary shares to shareholders in exchange for their pre-recapitalization shares. Founder Parties will receive Class B shares, while the SBCVC Shareholder, New Epoch Capital LP, and the New Horizon Shareholders will receive Class C shares. All other shareholders will receive Class A shares. The post-closing authorized share capital will total 2.5 billion shares, divided among the three classes.

The amendment also details the composition of the post-closing board of directors. The board will consist of nine members, with TDAC and its sponsor designating one Class I director, and ProLogium founder Yang Szu-Nan designating three directors. The SBCVC Shareholder and New Epoch will each have the right to appoint one Class I director. Additionally, the amendment changes the dispute resolution mechanism, replacing the Hong Kong International Arbitration Centre with the Singapore International Arbitration Centre.